Welcome to our dedicated page for Quanterix Corporation news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix Corporation stock.
Quanterix Corporation (NASDAQ: QTRX) is a pioneering life sciences company renowned for its groundbreaking ultra-sensitive diagnostic platform. This innovative technology measures individual proteins at concentrations that are up to 1000 times lower than the best immunoassays available today.
At the core of Quanterix's offerings is the Single Molecule Array (Simoa™) technology, which enables the detection and quantification of biomarkers that were previously difficult or impossible to measure. This advancement opens up new applications in various fields, including life sciences research, in-vitro diagnostics, companion diagnostics, and blood screening.
Founded by the esteemed scientist Dr. David Walt, who also co-founded Illumina, Quanterix benefits from a robust intellectual property portfolio initially developed at Tufts University. The company is venture capital-backed and has exclusive licensing rights to this broad IP portfolio.
Quanterix's product lineup is diverse and includes:
- Simoa platform
- Assay Kits
- LDTs & Assay Services
- Simoa p-Tau 217
- Simoa NfL LDT
- Simoa p-Tau 181 LDT
- HD-X Automated Immunoassay Analyzer
- SR-X Biomarker Detection System
- SP-X Imaging and Analysis System
- Simoa Accelerator Laboratory
- Homebrew - Custom Assay Development
- Uman NF-Light
The Simoa bead-based and planar array platforms are designed to detect protein biomarkers in low concentrations in blood, serum, and other fluids, which are undetectable using conventional analog immunoassay technologies.
Quanterix continues to push the boundaries of precision health for life sciences research and diagnostics, tackling significant unmet needs and contributing meaningfully to the scientific community.
Quanterix Corporation (NASDAQ: QTRX) announced the appointment of Michael Doyle as the new Chief Financial Officer (CFO) and Treasurer, effective July 12, 2021. Doyle replaces Shawn Stetson, who served in an interim capacity. Doyle brings significant experience as a public company CFO, having previously worked at Forrester Research, where he oversaw a team of 85 and managed multiple acquisitions while growing revenue from $200M to $500M. His appointment is seen as a strategic move to enhance the company’s prospects in advancing precision health through its digital biomarker analysis technology.
Quanterix Corporation (NASDAQ: QTRX) announced significant research utilizing its Simoa® technology to assess the plasma neurofilament light (NfL) biomarker for neurological disorders. Published in Nature Communications, this study involved 2,269 individuals and aims to enhance non-invasive diagnostics in neurodegenerative conditions. Findings confirm plasma NfL's potential in differentiating disorders and establishing age-related cutoffs vital for clinical applications. The research underscores NfL's role in precision health, bolstering Quanterix’s position as a leader in biomarker analysis.
Quanterix Corporation (NASDAQ:QTRX) has announced that its Chairman and CEO, Kevin Hrusovsky, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10 at 3:50 PM ET. The public can join the webcast via this link, with replays available for 90 days. Additionally, Hrusovsky will appear on The Bio Report podcast on June 3 at 4:00 PM EDT, accessible on various streaming platforms.
Quanterix Corporation (NASDAQ: QTRX) has appointed Masoud Toloue as President, effective June 9, 2021. Toloue brings extensive experience from PerkinElmer, where he significantly grew their diagnostics sector. The company highlighted advancements in diagnostics, particularly in response to COVID-19 and neurological disorders such as Multiple Sclerosis and Alzheimer’s. Toloue's expertise is expected to drive growth as he oversees the diagnostics business and corporate development. Quanterix aims to enhance precision health through innovative digital biomarker technology.
Quanterix Corporation (NASDAQ: QTRX) reported significant financial growth for Q1 2021, with total revenue increasing to $27.2M, up from $15.7M in Q1 2020, driven by a 86% rise in product revenues to $18.2M. The company achieved a gross margin of 60.1%, compared to 43.3% the previous year. Notably, Quanterix received Emergency Use Authorization for its Simoa® SARS-CoV-2 N Protein Antigen Test. The firm raised approximately $270M in a follow-on offering, strengthening its financial position. The demand for neurodegenerative disease assays, particularly for Alzheimer’s, remains robust.
Quanterix Corporation (NASDAQ: QTRX) will release its financial results for Q1 2021 on May 5, 2021, after market close. A conference call hosted by CEO Kevin Hrusovsky will take place at 4:30 p.m. ET to discuss the results and provide a business update. Interested parties can join by phone or through a live webcast available on Quanterix's website. The company specializes in digitizing biomarker analysis, aiming to enhance precision health through early disease detection and improved treatment methods across various therapeutic areas.
Quanterix Corporation (NASDAQ: QTRX) has appointed Laurie Olson to its Board of Directors, effective April 27, 2021. Olson brings over 30 years of pharmaceutical experience, having previously held key roles at Pfizer, including executive vice president of strategy and commercial operations. Her expertise in corporate strategy and market access aligns with Quanterix’s mission to advance precision health through innovative biomarker analysis. Olson's addition is expected to enhance the company's strategic direction as it seeks to leverage its Simoa technology for earlier disease detection and improved treatment.
Quanterix Corporation (NASDAQ:QTRX) announced a webinar set for April 23, 2021, focusing on advancements in neurological biomarkers such as pTau181 and pTau217. This session will feature prominent experts including CEO Kevin Hrusovsky and Dr. Charlotte Teunissen, discussing the opportunities presented by blood plasma biomarkers in conjunction with Simoa® technology for Alzheimer's Disease research. The event aims to highlight how these innovations can enhance clinical trials and diagnostics in the fight against Alzheimer's.
Quanterix Corporation (NASDAQ: QTRX) has appointed Shawn Stetson as interim CFO effective May 11, 2021, following Amol Chaubal's departure to Waters Corporation. The company is actively seeking a permanent successor. Kevin Hrusovsky, CEO, expressed confidence in Stetson's capabilities and acknowledged Chaubal's valuable contributions during his tenure. Quanterix focuses on digitizing biomarker analysis, offering innovative solutions aimed at enhancing healthcare delivery and disease detection, applicable in multiple therapeutic areas.
Quanterix Corporation (NASDAQ:QTRX) has reported successful utilization of its Simoa® technology for non-invasive detection of SARS-CoV-2 in various sample types. Published findings in Nature Communications suggest over 90% positive agreement and over 98% negative agreement with traditional PCR tests. The company emphasizes the importance of accurate, accessible testing amidst ongoing COVID-19 challenges. CEO Kevin Hrusovsky highlighted the potential for Simoa technology to enhance patient care and research, addressing issues like false negatives in current testing methods.
FAQ
What is the current stock price of Quanterix Corporation (QTRX)?
What is the market cap of Quanterix Corporation (QTRX)?
What is the core technology of Quanterix Corporation?
What are some applications of Quanterix's technology?
Who founded Quanterix Corporation?
What product platforms does Quanterix offer?
What makes Quanterix's diagnostic platform unique?
Is Quanterix publicly traded?
What significant achievements has Quanterix made recently?
What fluids can Quanterix's platforms detect biomarkers in?
Does Quanterix offer custom assay development?
What is the Simoa Accelerator Laboratory?
